[1]Part I：NCCN Practice Guidelines Tabular Summary（DD 3/20/13）：PET and PET/CT，Part Ⅱ：NCCN Practice Guidelines Narrative Summary：PET and PET/CT，NCCN Guidelines for Treatment of Cancer by Site．

[2]Fletcher JW，Djulbegovic B，Soares HP，et al．Recommendations on the use of F-18-FDG PET in oncology．J Nucl Med，2008，49：480-508．

[3]Kagna O，Solomonov A，Keidar Z，et al．The value of FDG-PET/CT in assessing single pulmonary nodules in patients at high risk of lung cancer．Eur J Nucl Med Mol Imaging，2009，36（6）：997-1004．

[4]Tian J，Yang X，Yu L，et al．A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3'-deoxy-3'-18F- fluorothymidine and 18F-FDG．J Nucl Med，2008，49（2）：186-194．

[5]陈萍，田嘉禾，杨小丰，等． ¹⁸F-FLT与 ¹⁸F-FDG PET/CT不同判断方法鉴别肺良恶性肿瘤诊断效能的比较．中华核医学杂志，2008，28（03）：151-154．

[6]张国建，王雪梅，田嘉禾，等． ¹⁸F-FLT联合 ¹⁸F-FDG PET/CT显像对纵隔淋巴结良恶性的诊断价值．中华核医学与分子影像杂志，2013，33（01）：34-38．

[7]Li X，Zhang H，Xing L，et al．Mediastinal lymph nodes staging by 18F-FDG PET/CT for early stage non-small cell lung cancer：a multicenter study．Radiother Oncol，2012，102（2）：246-250．

[8]Facey K，Bradbury I，Laking G，et al．Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers．Health Technol Assess，2007，11（44）：iii-iv，xi-267．

[9]Reske SN，Kotzerke J．FDG-PET for clinical use．Results of the 3rd ed German Interdisciplinary Consensus Conference，"Onko-PETⅢ"，21 July and 19 September 2000．Eur J Nucl Med，2001，28（11）：1707-1723．

[10]Barrington SF，Mikhaeel NG，Kostakoglu L，et al．Role of Imaging in the Staging and Response Assessment of Lymphoma：Consensus of the International Conference on Malignant Lymphomas Imaging Working Group．J Clin Oncol，2014，32（27）：3048-3058．

[11]Cheson BD，Fisher RI，Barrington SF，et al．Recommendations for Initial Evaluation，Staging，and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma：The Lugano Classification．J Clin Oncol，2014，32（27）：3059-3068．

[12]Völker T，Denecke T，Steffen I，et al．Positron emission tomography for staging of pediatric sarcoma patients：results of a prospective multicenter trial．J Clin Oncol，2007，25（34）：5435-5441．

[13]Rigacci L，Vitolo U，Nassi L，et al．Positron emission tomography in the staging of patients with Hodgkin’s lymphoma．A prospective multicentric study by the Intergruppo Italiano Linfomi．Ann Hematol，2007，86（12）：897-903．

[14]Lonneux M，Hamoir M，Reychler H，et al．Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma：a multicenter prospective study．J Clin Oncol，2010，28（7）：1190-1195．

[15]Uyl-de Groot CA，Senft A，de Bree R，et al．Chest CT and whole-body 18F-FDG PET are cost-effective in screening for distant metastases in head and neck cancer patients．J Nucl Med，2010，51（2）：176-182．

[16]Senft A，de Bree R，Hoekstra OS，et al．Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET：a prospective multicenter trial．Radiother Oncol，2008，87（2）：221-229．

[17]Kim BT，Lee KS，Shim SS，et al．Stage T1 Non-Small Cell Lung Cancer：Preoperative Mediastinal Nodal Staging with Integrated FDG PET/CT-A Prospective Study．Radiology，2006，241（2）：501-509．

[18]Brush J，Boyd K，Chappell F，et al．The value of FDG positron emission tomography/computerised tomography（PET/CT）in pre-operative staging of colorectal cancer：a systematic review and economic evaluation．Health Technol Assess，2011，15（35）：1-192．

[19]Kitajima K，Murakami K，Kanegae K，et al．Clinical impact of whole body FDG-PET for recurrent biliary cancer：a multicenter study．Ann Nucl Med，2009，23（8）：709-715．

[20]Baiocchi GL，Marrelli D，Verlato G，et al．Follow-up after gastrectomy for cancer：an appraisal of the italian research group for gastric cancer．Ann Surg Oncol，2014，21（6）：2005-2011．

[21]Fulham MJ，Carter J，Baldey A，et al．The impact of PET-CT in suspected recurrent ovarian cancer：A prospective multi-centre study as part of the Australian PET Data Collection Project．Gynecol Oncol，2009，112（3）：462-468．

[22]Beasley GM，Parsons C，Broadwater G，et al．A multicenter prospective evaluation of the clinical utility of F-18 FDG-PET/CT in patients with AJCC stage ⅢB or ⅢC extremity melanoma．Ann Surg，2012，256（2）：350-356．

[23]Itti E，Meignan M，Berriolo-Riedinger A，et al．An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma：comparison between Deauville criteria and ΔSUVmax．Eur J Nucl Med Mol Imaging，2013，40（9）：1312-1320．

[24]Terasawa T，Nagai H．Current clinical evidence on interim fluorine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes．Leuk Lymphoma，2009，50（11）：1750-1752．

[25]Bonichon F，Palussière J，Godbert Y，et al．Diagnostic accuracy of ¹⁸F-FDG PET/CT for assessing response to radiofrequency ablation treatment in lung metastases：a multicentre prospective study．Eur J Nucl Med Mol Imaging，2013，40（12）：1817-1827．

[26]Hutchings M，Loft A，Hansen M，et al．FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma．Blood，2006，107（1）：52-59．

[27]de Geus-Oei LF，Vriens D，Arens AIJ，et al．FDG-PET/CT based response-adapted treatment．Cancer Imaging，2012，12（2）：324-335．

[28]Terasawa T，Lau J，Bardet S，et al．Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin’s lymphoma and diffuse large B-cell lymphoma：a systematic review．J Clin Oncol，2009，27（11）：1906-1914．

[29]Pregno P，Chiappella A，BellòM，et al．Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP．Blood，2012，119（9）：2066-2073．

[30]Palie O，Michel P，Ménard JF，et al．The predictive value of treatment response using FDG PET performed on day 21 of chemoradiotherapy in patients with oesophageal squamous cell carcinoma．A prospective，multicentre study（RTEP3）．Eur J Nucl Med Mol Imaging，2013，40（9）：1345-1355．

[31]Lorenzen S，von Gall C，Stange A，et al．Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction（AEG）：The Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment：HICON trial．BMC Cancer，2011，11：266-274．

[32]Johansen J，Buus S，Loft A，et al．Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor．Results from the DAHANCA-13 study．Head Neck，2008，30（4）：471-478．

[33]Grégoire V，Chiti AJ．Molecular imaging in radiotherapy planning for head and neck tumors．Nucl Med，2011，52（3）：331-334．

[34]Pommier P，Touboul E，Chabaud S，et al．Impact o（f18）F-FDG PET on treatment strategy and 3D radiotherapy planning in non-small cell lung cancer：A prospective multicenter study．AJR Am J Roentgenol，2010，195（2）：350-355．

[35]Pommier P，Dussart S，Girinsky T，et al．Impact of ¹⁸F-fluoro-2- deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease：a prospective multicenter study．Int J Radiat Oncol Biol Phys，2011，79（3）：823-828．

[36]Minamimoto R，Senda M，Uno K，et al．Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey．Ann Nucl Med，2007，21（9）：481-498．

[37]Daube-Witherspoon ME，Karp JS，Casey ME，et al．PET performance measurements using the NEMA NU 2-2001 standard．The Journal of Nuclear Medicine，2002，43（10）：1398-1409．

[38]万良荣，黄钢，孙晓光，等．PET/CT的质量控制和日常维护．上海第二医科大学学报，2005，12（25）：1303-1305．

[39]Habib Zaidi．Is radionuclide transmission scanning obsolete for dual-modality PET/CT systems？European Journal of Nuclear Medicine and Molecular Imaging，2007，34（6）：815-818．

[40]Dale L，Bailey．Transmission scanning in emission tomography．European Journal of Nuclear Medicine，1998，25（7）：774-787．

[41]Carney JP，Townsend DW，Rappoport V，et al．Method for transforming CT images for attenuation correction in PET/CT imaging．Med Phys，2006，33（4）：976-983．

[42]陆汉魁．PET显像的散射校正和衰减校正．中华核医学杂志，2004，1（24）：56-58．

[43]Marsden PK．Quantification in PET：What is it Can we do it？Do we need it？Nucl Med Commun，2004，25（7）：635-636．

[44]Bacharach SL，Sundaram SK．The 18F-FDG in cardiology and oncology：the bitter with the sweet．J Nucl Med，2002，43（11）：1542-1544．

[45]Wolfgang AW．Use PET for monitoring cancer therapy and for predicting outcome．J Nucl Med，2005，46（6）：983-995．

[46]刘建军，陈虞梅，黄刚等．氟-18-氟代脱氧葡萄糖PET/CT不同时相延迟显像的比较．中国临床医学，2008，15（2）：264-268．

[47]Mertens LS，Fioole-Bruining A，Vegt E，et al．Detecting primary bladder cancer using delayed（18）F-2-fluoro-2-deoxy-D-glucise-positron emission tomography/computed tomography imaging after forced diuresus．Indian J Nucl Med，2012；27（3）：145-150．

[48]张永学，吴志坚，贾清，等． ¹⁸F-FDG PET双时相显像在鉴别良恶性病变中的价值．中国医学影像技术，2006（09）：1415-1417．

[49]李洪生，吴湖炳，王巧愚，等．呋塞米介入（-18）F-FDG PET/CT双时相显像对膀胱癌的诊断价值．核技术．2014，02：33-38．

[50]Zhang H，Pourdehnad M，Lambright ES，et al．Dual time point 18F-FDG PET imaging for differentiating magnant from inflammatory processes．J Nucl Med，2001，42（9）：1412-1417．

[51]Matthies A，Hickeson M，Cuchiara A，et，al．Dual time point F-18-FDG PET for the eveluation of pulmonary nodules．J Nucl Med，2002，43（7）：871-875．

[52]赵军，林祥通，管一晖，等．双时相PET显像在肺良恶性病变鉴别诊断中的应用．中华核医学杂志，2003，23（1）：8-10．

[53]Beyer T，Townsend DW，Brun T，et al．A combined PET/CT scanner for clinical oncology．J Nucl Med，2000，41：1369-1379．

[54]Shreve PD．Adding structure function．J nucl Med，2000，41：1380-1382．

[55]Nakamoto Y，Osman M，Cohade C，et al．PET/CT：Comparison of quantitative tracer uptake between germanium and CT transmission attenuation-corrected images．J Nucl Med，2002，43：1137-1143．

[56]Goerres GW，Kamel E，Seifert B，et al．Accuracy of image coregistration of pulmonary lesions in patients with non-small cell lung cancer using an integrated PET/CT system．J Nucl Med，2002，43：1469-1475．

[57]Osman MM，Cohade C，Nakamoto Y，et al．Clinically significant inaccurate localization of lesions with PET/ CT：frequency in 300 patients．J Nucl Med，2003，44：240-243．

[58]Cohade C，Osman M，Pannu HK，et al．Uptake in supraclavicular area fa（“USA-Fat”）：description on 18F-FDG PET/CT．J Nucl Med，2003，44：170-176．

[59]Mylene T，Chitra V，Brett W，et al．PET/CT in the thorax：pitfalls．Radiol Clin N Am，2014，52：17-25．

[60]Patrick J．Role of positron emission tomography/computed tomography in bone maligancies．Radiol Clin N Am，2013，51：845-864．

[61]Paul S，Todd F．Role of positron emission tomography-computed tomography in pulmonary neoplasms．Radiol Clin N Am，2013，51：767-779．

[62]Antoch G，Freudenberg LS，Egelhof T，et al．Focal tracer uptake：a potential artifact in contrast-enhanced dual-modality PET/CT scans．J Nucl Med，2002，43：1339-1342．

[63]Cohade C，Osman M，Nakamoto Y，et al．Initial experience with oral contrast in PET/CT：phantom and clinical studies．J Nucl Med，2003，44：412-416．

[64]Edward JE．Role of positron emission tomography/computed tomography（PET/CT）in head and neck cancer．Radiol Clin N Am，2013，51：881-893．

[65]Allen-Auerbach M，de Vos S，Czernin J．PET/computed tomography and lymphoma．Radiol Clin N Am，2013，51：833-844．

[66]Kevin P，Won S．Role of positron emission tomography-computed tomography in gastrointestinal malignancies．Radiol Clin N Am，2013，51：799-831．

[67]Boellaard R．Need for standardization of 18F-FDG PET/CT for treatment response assessments．J Nucl Med，2011，52 Suppl 2：93S-100S．

[68]Boellaard R．Standards for PET image acquisition and quantitative data analysis．J Nucl Med，2009，50 suppl 1：11S-20S．

[69]葛全序，朱仁娟，刘庆伟，等．（18）F-FDG PET/CT结合高分辨率CT对孤立性肺结节的诊断价值．中华核医学杂志，2005，25（5）：264-266．

[70]Li Y，Su M，Li F，et al．The value of ¹⁸F-FDG-PET/CT in the differential diagnosis of solitary pulmonary nodules in areas with a high incidence of tuberculosis．Ann Nucl Med，2011，25（10）：804-811．

[71]Groves AM，Kayani I，Dickson JC，et al．Oral contrast medium in PET/CT：should you or shouldn’t you？Eur J Nucl Med Mol Imaging，2005，32（10）：1160-1166．

[72]Sun XG，Huang G，Liu JJ，et al．Comparison of the effect of positive and negative oral contrast agents on（18）F-FDG PET/CT scan．Hell J Nucl Med，2009，12（2）：115-118．

[73]Goerres GW，Schuknecht B，Schmid DT，et al．Positron emission tomography/computed tomography for staging and restaging of head and neck cancer：comparison with positron emission tomography read together with contrast-enhanced computed tomography．Clin Imaging，2008，32（6）：431-437．

[74]Yoshida K，Suzuki A，Nagashima T，et al．Staging primary head and neck cancers with（18）F-FDG PET/CT：is intravenous contrast administration really necessary？Eur J Nucl Med Mol Imaging，2009，36（9）：1417-1424．

[75]Boellaard R，Delgado-Bolton R，Oyen WJ，et al．FDG PET/CT：EANM procedure guidelines for tumour imaging：version 2.0．Eur J Nucl Med Mol Imaging，2015，42（2）：328-354．

[76]Delbeke D，Coleman RE，Guiberteau MJ，et al．Procedure guideline for tumor imaging with ¹⁸F-FDG PET/CT 1.0．J Nucl Med，2006，47：885-895．

[77]中华医学会核医学分会． ¹⁸F-FDG PET/CT肺占位病变显像技术操作和临床应用指导原则（建议版2008）．中华核医学杂志，2008，28：359-360．

[78]潘中允．实用核医学．北京：人民卫生出版社，2014．

[79]Ronald B，Workman Jr．PET/CT essentials for clinical practice．New York：Springer，2006．

[80]Peter E，Dominique D，Dale L．B，et al．Positron Emission Tomography Clinical Practice．London：Springer-Verlag London Limited，2006．

[81]Czernin J，Dahlbom M，Ratib O，et al．Atlas of PET/CT Imaging in Oncology．Berlin：Springer-Verlag Berlin Heidelberg，2004．

[82]李天然，赵春雷，钱根年，等． ¹⁸F-FDG PET/CT伪影和不常见生理性摄取分析．中华核医学杂志，2006，26（5）：295-298．

[83] Krause BJ，Beyer T，Bockisch A，et al．FDG-PET/CT in oncology．German guideline．Nuklear medizin，2007，46：291-301．

[84]Boellaard R，Oyen WJ，Hoekstra CJ，et al．The Netherlands protocol for standardization and quantification of FDG wholebody PET studies in multi-centre trials．Eur J Nucl Med Mol Imaging，2008，35：2320-2333．

[85]Fletcher JW，Djulbegovic B，Soares HP et al．Recommendations on the use of F-18-FDG PET in oncology．J Nucl Med，2008，49：480-508．